Aviva
AMPH icon

Aviva’s Amphastar Pharmaceuticals AMPH Stock Holding History

Aviva’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,959
Closed -$1.5M – 966
2023
Q1 		$1.5M Buy
39,959
+16,636
+71% +$545K 0.01% 730
2022
Q4 		$654K Sell
23,323
-31,154
-57% -$905K ﹤0.01% 945
2022
Q3 		$1.53M Sell
54,477
-2,270
-4% -$74.1K 0.01% 769
2022
Q2 		$1.97M Buy
+56,747
New +$2.03M 0.01% 823

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aviva's AMPH Position: Q2 2023 in Review

Aviva sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2023, closing a stake of 39,959 shares — an estimated $1.5M sold.

Aviva first reported a position in AMPH in Q2 2022 and held it in 4 quarters. The position peaked at $1.97M in Q2 2022. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2023.

  • Aviva reported no remaining Amphastar Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Aviva sold 39,959 Amphastar Pharmaceuticals shares in Q2 2023, an estimated $1.5M.
  • Aviva first reported a position in Amphastar Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Aviva's Amphastar Pharmaceuticals position peaked at $1.97M in Q2 2022.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2023.

Based on Aviva's 13F filing for Q2 2023, filed 10 Aug 2023.